MENU

Continuing Medical Education

Continuing Medical Education (CME) at Fox Chase Cancer Center is coordinated through the Temple Health CME Program. Their purpose is to support the educational needs of the medical staffs of both Fox Chase Cancer Center and Jeanes Hospital’s integrated campus in order to improve patient care.

The CME Program embraces evidence-based programs which promote new concepts in patient safety and enhance excellence in care. We strive to improve patient outcomes through an interdisciplinary approach to patient-centered care which strengthens interpersonal communication between healthcare providers and referring physicians.

The Temple Health CME Program is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

See Fox Chase Cancer Center CME Events now open for registration.

For more information about the CME Program, please contact Lucia Tono-Ramirez at Lucia.Tono-Ramirez@tuhs.temple.edu, 215-728-3797, or 215-728-2026 (fax).

Upcoming Programs in the 2017 CME Program Series

Review Highlights of the San Antonio Breast Cancer Symposium
January 19, 2017
6-9 p.m.

The San Antonio Breast Cancer Symposium (SABCS) is an international forum for the presentation of state-of-theart information on the biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. This program is designed to help oncologists, gynecologists, and radiologists translate the data from key presentations from the symposium into practice.
Register

New Directions in the Diagnosis and Treatment of Hematologic Cancers Symposium
February 4, 2017

Hematologic malignancies’ research is growing at a rapid pace, increasing the complexity of the field. Advances in the understanding of the mechanisms of hematologic malignancies have resulted in the development of new prognostic models, novel therapies and improvements in disease management. It is essential to our community to stay abreast of the latest findings in the field and of their potential impact on clinical practice.

This symposium will provide attendees with cutting-edge updates and perspectives on new diagnostic tools and management options of hematologic malignancies including genetic profiling, cytogenetics, molecular diagnosis, risk adopted strategies and novel therapies recently approved by the FDA. Advances in the understanding of aggressive lymphoma and Hodgkin lymphoma, myelodysplasia, plasma cell dyscrasia, acute leukemia and myeloproliferative disease, indolent lymphoma, T-Cell lymphoma and HIV lymphoma will be addressed. Education on consultative hematology will also be addressed.

Advances in Thoracic Oncology Conference
April 8, 2017

The rapid influx of new information about the management of thoracic malignancies and its dynamic effect on clinical practice poses significant challenges to physicians who must determine the appropriate options when developing treatment plans for patients with these cancers.

This conference is designed as a forum for discussion of advances in technology and treatment that will help participants determine appropriate strategies for managing patients with thoracic cancers and advanced lung disease. This conference will also help participants navigate the challenges of lung cancer screening.

Atlantic Regional Hematopathology Meeting – ARHM
May 20, 2017 – tentative

Advances in hematopathology are evolving at a rapid rate. However, pathologists are often limited in the cases that they are exposed to during their daily practice, making it difficult to remain current with the latest advances.

Using a case review format, this conference will provide participants with the opportunity to review complex cases and discuss approaches to diagnosing these cases. Participants will review indicators/markers and test results to understand the reason that the diagnosis was reached. This format will assist hematopathologists, other pathologists, fellows and residents to enhance their ability to incorporate recent molecular immunophenotypic and genetic information in the interpretation.

Connect with Fox Chase